Daniel Rauh

List of Publications by Year
in descending order

88 papers	3,963 citations	117625 34 h-index	128289 60 g-index
94 all docs	94 docs citations	94 times ranked	5868 citing authors

#	Article	IF	Citations
1	Covalent Allosteric Inhibitors of Akt Generated Using a Click Fragment Approach. ChemMedChem, 2022, 17, .	3.2	3
2	Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 6643-6655.	6.4	12
3	Persister state-directed transitioning and vulnerability in melanoma. Nature Communications, 2022, 13, .	12.8	20
4	Design and synthesis of Nrf2-derived hydrocarbon stapled peptides for the disruption of protein-DNA-interactions. PLoS ONE, 2022, 17, e0267651.	2.5	2
5	Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain. Cancer Discovery, 2021, 11, 108-125.	9.4	47
6	Cellular model system to dissect the isoform-selectivity of Akt inhibitors. Nature Communications, 2021, 12, 5297.	12.8	16
7	Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases. Journal of Medicinal Chemistry, 2020, 63, 40-51.	6.4	9
8	Targeting Her2-insYVMA with Covalent Inhibitorsâ€"A Focused Compound Screening and Structure-Based Design Approach. Journal of Medicinal Chemistry, 2020, 63, 11725-11755.	6.4	7
9	Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands. ACS Medicinal Chemistry Letters, 2020, 11, 2484-2490.	2.8	26
10	KRasG12C inhibitors in clinical trials: a short historical perspective. RSC Medicinal Chemistry, 2020, 11, 760-770.	3.9	95
11	Spotlight on AKT: Current Therapeutic Challenges. ACS Medicinal Chemistry Letters, 2020, 11, 225-227.	2.8	30
12	Conformational selection vs. induced fit: insights into the binding mechanisms of p38Î± MAP Kinase inhibitors. Chemical Communications, 2020, 56, 8818-8821.	4.1	6
13	Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC. Cell Reports, 2020, 31, 107568.	6.4	15
14	Mutant-Specific Targeting of Ras G12C Activity by Covalently Reacting Small Molecules. Cell Chemical Biology, 2019, 26, 1338-1348.	5.2	12
15	Covalentâ€Allosteric Inhibitors to Achieve Akt Isoformâ€Selectivity. Angewandte Chemie, 2019, 131, 18999-19005.	2.0	7
16	Covalentâ€Allosteric Inhibitors to Achieve Akt Isoformâ€Selectivity. Angewandte Chemie - International Edition, 2019, 58, 18823-18829.	13.8	44
17	Characterization of Covalent Pyrazolopyrimidineâ€"MKK7 Complexes and a Report on a Unique DFG-in/Leu-in Conformation of Mitogen-Activated Protein Kinase Kinase 7 (MKK7). Journal of Medicinal Chemistry, 2019, 62, 5541-5546.	6.4	12
18	Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer. Cancer Research, 2019, 79, 2367-2378.	0.9	60

#	Article	IF	Citations
19	2-Azo-, 2-diazocine-thiazols and 2-azo-imidazoles as photoswitchable kinase inhibitors: limitations and pitfalls of the photoswitchable inhibitor approach. Photochemical and Photobiological Sciences, 2019, 18, 1398-1407.	2.9	53
20	Targeting the MKK7â€“JNK (Mitogen-Activated Protein Kinase Kinase 7â€“c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 2843-2848.	6.4	18
21	Co-crystal structure determination and cellular evaluation of 1,4-dihydropyrazolo[4,3-c] [1,2] benzothiazine 5,5-dioxide p38Î± MAPK inhibitors. Biochemical and Biophysical Research Communications, 2019, 511, 579-586.	2.1	6
22	Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt. Chemical Science, 2019, 10, 3573-3585.	7.4	49
23	Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S. Chemical Science, 2019, 10, 10789-10801.	7.4	25
24	A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives. Scientific Reports, 2019, 9, 14.	3.3	28
25	Targeting EGFR Ex20 mutant lung cancer with the wild type sparing kinase inhibitor PRB001.. Journal of Clinical Oncology, 2019, 37, e14718-e14718.	1.6	1
26	Try Me: Promiscuous Inhibitors Still Allow for Selective Targeted Protein Degradation. Cell Chemical Biology, 2018, 25, 4-6.	5.2	16
27	Augmented Reality in Scientific Publicationsâ€”Taking the Visualization of 3D Structures to the Next Level. ACS Chemical Biology, 2018, 13, 496-499.	3.4	28
28	Lessons To Be Learned: The Molecular Basis of Kinaseâ€Targeted Therapies and Drug Resistance in Nonâ€Small Cell Lung Cancer. Angewandte Chemie - International Edition, 2018, 57, 2307-2313.	13.8	36
29	Lektion gelernt? Die molekularen Grundlagen von Kinaseâ€gerichteten Therapien und Wirkstoffresistenz im nichtâ€kleinzelligen Lungenkrebs. Angewandte Chemie, 2018, 130, 2329-2335.	2.0	1
30	Direct monitoring of the conformational equilibria of the activation loop in the mitogen-activated protein kinase p38Î±. Chemical Communications, 2018, 54, 12057-12060.	4.1	10
31	Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nature Communications, 2018, 9, 4655.	12.8	107
32	Donated chemical probes for open science. ELife, 2018, 7, .	6.0	80
33	Insights into the Kinetics of the Resistance Formation of Bacteria against Ciprofloxacin Poly(2-methyl-2-oxazoline) Conjugates. Bioconjugate Chemistry, 2018, 29, 2671-2678.	3.6	10
34	RASPELD to Perform Highâ€End Screening in an Academic Environment toward the Development of Cancer Therapeutics. ChemMedChem, 2018, 13, 2065-2072.	3.2	5
35	C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?. ACS Medicinal Chemistry Letters, 2018, 9, 779-782.	2.8	56
36	Chemical modulation of transcription factors. MedChemComm, 2018, 9, 1249-1272.	3.4	11

#	Article	IF	Citations
37	Eine ungewÃ¶hnliche intramolekulare Halogenbindung fÃ¼hrt zu konformationeller Selektion. Angewandte Chemie, 2018, 130, 10120-10126.	2.0	0
38	An Unusual Intramolecular Halogen Bond Guides Conformational Selection. Angewandte Chemie - International Edition, 2018, 57, 9970-9975.	13.8	12
39	Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry, 2017, 60, 2361-2372.	6.4	43
40	Optimized Target Residence Time: Typeâ€…I Inhibitors for p38Î± MAP Kinase with Improved Binding Kinetics through Direct Interaction with the Râ€šspine. Angewandte Chemie - International Edition, 2017, 56, 5363-5367.	13.8	20
41	Characterization of Covalent-Reversible EGFR Inhibitors. ACS Omega, 2017, 2, 1563-1575.	3.5	18
42	Phenotypic Identification of a Novel Autophagy Inhibitor Chemotype Targeting Lipid Kinase VPS34. Angewandte Chemie - International Edition, 2017, 56, 8153-8157.	13.8	45
43	Phenotypic Identification of a Novel Autophagy Inhibitor Chemotype Targeting Lipid Kinase VPS34. Angewandte Chemie, 2017, 129, 8265-8269.	2.0	8
44	Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site. Journal of Medicinal Chemistry, 2017, 60, 5613-5637.	6.4	77
45	Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT. Journal of Medicinal Chemistry, 2017, 60, 8801-8815.	6.4	7
46	Covalent Lipid Pocket Ligands Targeting p38Î± MAPK Mutants. Angewandte Chemie - International Edition, 2017, 56, 13232-13236.	13.8	18
47	Design, Synthesis, and Biological Evaluation of Novel Type I¹/₂ p38Î± MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine. Journal of Medicinal Chemistry, 2017, 60, 8027-8054.	6.4	24
48	Kovalente Liganden zur Adressierung einer lipophilen Bindetasche in der MAPKâ€…p38Î±. Angewandte Chemie, 2017, 129, 13415-13419.	2.0	0
49	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry, 2017, 60, 7725-7744.	6.4	24
50	Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. Cell Reports, 2017, 20, 2833-2845.	6.4	40
51	Optimized 4,5-Diarylimidazoles as Potent/Selective Inhibitors of Protein Kinase CK1Î´ and Their Structural Relation to p38Î± MAPK. Molecules, 2017, 22, 522.	3.8	35
52	Structure-based design, synthesis and crystallization of 2-arylquinazolines as lipid pocket ligands of p38Î± MAPK. PLoS ONE, 2017, 12, e0184627.	2.5	11
53	Monitoring Conformational Changes in the Receptor Tyrosine Kinase EGFR. ChemBioChem, 2016, 17, 990-994.	2.6	1
54	Inhibition wirkstoffresistenter Mutationsvarianten der Rezeptortyrosinkinase EGFR. Angewandte Chemie, 2016, 128, 11069-11073.	2.0	4

#	Article	IF	Citations
55	Insight into the Inhibition of Drugâ€Resistant Mutants of the Receptor Tyrosine Kinase EGFR. Angewandte Chemie - International Edition, 2016, 55, 10909-10912.	13.8	54
56	A cascade screening approach for the identification of Bcr-Abl myristate pocket binders active against wild type and T315I mutant. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3436-3440.	2.2	1
57	Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer. ACS Medicinal Chemistry Letters, 2016, 7, 2-5.	2.8	75
58	Covalentâ€Allosteric Kinase Inhibitors. Angewandte Chemie - International Edition, 2015, 54, 10313-10316.	13.8	87
59	Monitoring Ligandâ€Induced Conformational Changes for the Identification of Estrogen Receptor Agonists and Antagonists. Angewandte Chemie - International Edition, 2015, 54, 4379-4382.	13.8	19
60	A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer. Cell, 2015, 162, 146-159.	28.9	100
61	Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR. Bioorganic and Medicinal Chemistry, 2015, 23, 2767-2780.	3.0	37
62	Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach. Journal of Medicinal Chemistry, 2015, 58, 6844-6863.	6.4	92
63	Discovery of Inter-Domain Stabilizersâ€"A Novel Assay System for Allosteric Akt Inhibitors. ACS Chemical Biology, 2015, 10, 279-288.	3.4	22
64	FLiK. Methods in Enzymology, 2014, 548, 147-171.	1.0	8
65	Cell-Autonomous and Nonâ€"Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer. Cancer Discovery, 2014, 4, 246-257.	9.4	93
66	Targeting Gain of Function and Resistance Mutations in Abl and KIT by Hybrid Compound Design. Journal of Medicinal Chemistry, 2013, 56, 5757-5772.	6.4	17
67	Metabolically Stable Dibenzo[b,e]oxepin-11(6H)-ones as Highly Selective p38 MAP Kinase Inhibitors: Optimizing Anti-Cytokine Activity in Human Whole Blood. Journal of Medicinal Chemistry, 2013, 56, 8561-8578.	6.4	26
68	Dibenzosuberones as p38 Mitogen-Activated Protein Kinase Inhibitors with Low ATP Competitiveness and Outstanding Whole Blood Activity. Journal of Medicinal Chemistry, 2013, 56, 241-253.	6.4	31
69	Selective Detection of Allosteric Phosphatase Inhibitors. Journal of the American Chemical Society, 2013, 135, 6838-6841.	13.7	33
70	Strategies for the Selective Regulation of Kinases with Allosteric Modulators: Exploiting Exclusive Structural Features. ACS Chemical Biology, 2013, 8, 58-70.	3.4	170
71	Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer. Journal of Clinical Oncology, 2012, 30, 3417-3420.	1.6	61
72	Direct Binding Assay for the Detection of Type IV Allosteric Inhibitors of Abl. Journal of the American Chemical Society, 2012, 134, 9138-9141.	13.7	34

#	Article	IF	Citations
73	Targeting GSK3 from Ustilago maydis: Type-II Kinase Inhibitors as Potential Antifungals. ACS Chemical Biology, 2012, 7, 1257-1267.	3.4	18
74	Targeting the Hinge Glycine Flip and the Activation Loop: Novel Approach to Potent p38Î± Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 7862-7874.	6.4	36
75	Fluorophore Labeled Kinase Detects Ligands That Bind within the MAPK Insert of p38Î± Kinase. PLoS ONE, 2012, 7, e39713.	2.5	32
76	Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor. Nature Chemical Biology, 2012, 8, 141-143.	8.0	109
77	Structure-based design, synthesis and biological evaluation of N-pyrazole, Nâ€²-thiazole urea inhibitors of MAP kinase p38Î±. European Journal of Medicinal Chemistry, 2012, 48, 1-15.	5.5	29
78	ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors. Clinical Cancer Research, 2011, 17, 7394-7401.	7.0	179
79	Characterization of Irreversible Kinase Inhibitors by Directly Detecting Covalent Bond Formation: A Tool for Dissecting Kinase Drug Resistance. ChemBioChem, 2010, 11, 2557-2566.	2.6	40
80	Proteus in the World of Proteins: Conformational Changes in Protein Kinases. Archiv Der Pharmazie, 2010, 343, 193-206.	4.1	72
81	Small-molecule inhibition of APT1 affects Ras localization and signaling. Nature Chemical Biology, 2010, 6, 449-456.	8.0	353
82	Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation. Cancer Research, 2010, 70, 868-874.	0.9	191
83	Displacement Assay for the Detection of Stabilizers of Inactive Kinase Conformations. Journal of Medicinal Chemistry, 2010, 53, 357-367.	6.4	26
84	Fluorophore Labeling of the Glycine-Rich Loop as a Method of Identifying Inhibitors That Bind to Active and Inactive Kinase Conformations. Journal of the American Chemical Society, 2010, 132, 4152-4160.	13.7	50
85	High-Throughput Screening To Identify Inhibitors Which Stabilize Inactive Kinase Conformations in p38Î±. Journal of the American Chemical Society, 2009, 131, 18478-18488.	13.7	80
86	Development of a Fluorescent-Tagged Kinase Assay System for the Detection and Characterization of Allosteric Kinase Inhibitors. Journal of the American Chemical Society, 2009, 131, 13286-13296.	13.7	140
87	Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR. Bioorganic and Medicinal Chemistry, 2008, 16, 3482-3488.	3.0	88
88	Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nature Chemical Biology, 2007, 3, 229-238.	8.0	190